Multifunctional Albumin–MnO2 Nanoparticles Modulate Solid Tumor Microenvironment by Attenuating Hypoxia, Acidosis, Vascular Endothelial Growth Factor and Enhance Radiation Response
Source abstract
Abstract
Insufficient oxygenation (hypoxia), acidic pH (acidosis), and elevated levels of reactive oxygen species (ROS), such as H2O2, are characteristic abnormalities of the tumor microenvironment (TME). These abnormalities promote tumor aggressiveness, metastasis, and resistance to therapies. To date, there is no treatment available for comprehensive modulation of the TME. Approaches so far have been limited to regulating hypoxia, acidosis, or ROS individually, without accounting for their interdependent effects on tumor progression and response to treatments. Hence we have engineered multifunctional and colloidally stable bioinorganic nanoparticles composed of polyelectrolyte-albumin complex and MnO2 nanoparticles (A-MnO2 NPs) and utilized the reactivity of MnO2 toward peroxides for regulation of the TME with simultaneous oxygen generation and pH increase. In vitro studies showed that these NPs can generate oxygen by reacting with H2O2 produced by cancer cells under hypoxic conditions. A-MnO2 NPs simultaneously increased tumor oxygenation by 45% while increasing tumor pH from pH 6.7 to pH 7.2 by reacting with endogenous H2O2 produced within the tumor in a murine breast tumor model. Intratumoral treatment with NPs also led to the downregulation of two major regulators in tumor progression and aggressiveness, that is, hypoxia-inducible factor-1 alpha and vascular endothelial growth factor in the tumor. Combination treatment of the tumors with NPs and ionizing radiation significantly inhibited breast tumor growth, increased DNA double strand breaks and cancer cell death as compared to radiation therapy alone. These results suggest great potential of A-MnO2 NPs for modulation of the TME and enhancement of radiation response in the treatment of cancer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism · Angiogenesis and VEGF in Cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutical Sciences, Leslie L. Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario M5S 3M2, Canada
Princess Margaret Cancer Center, The Campbell Family Institute for Cancer Research, University Health Network, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
Department of Medical Biophysics, University of Toronto, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
Funding
Natural Sciences and Engineering Research Council of Canada
References (46)
Show source-provided references
1. Gatenby R. A. · Nat. Rev. Cancer · 2008 · 8 · 5610.1038/nrc2255 ↗
2. Rockwell S. · Curr. Mol. Med. · 2009 · 9 · 44210.2174/156652409788167087 ↗
3. Lundgren K. · Cell. Mol. Life Sci. · 2007 · 64 · 323310.1007/s00018-007-7390-6 ↗
4. Vaupel P. · Cancer Res. · 1991 · 51 · 3316
5. Bertout J. A. · Nat. Rev. Cancer · 2008 · 8 · 96710.1038/nrc2540 ↗
6. Rademakers S. E. · Mol. Oncol. · 2008 · 2 · 4110.1016/j.molonc.2008.03.006 ↗
7. Semenza G. · Trends Pharmacol. Sci. · 2012 · 33 · 20710.1016/j.tips.2012.01.005 ↗
8. Liao D. · Cancer Metastasis Rev. · 2007 · 26 · 28110.1007/s10555-007-9066-y ↗
9. Forsythe J. A. · Mol. Cell. Biol. · 1996 · 16 · 460410.1128/MCB.16.9.4604 ↗
10. Gatenby R. A. · Nat. Rev. Cancer. · 2004 · 4 · 89110.1038/nrc1478 ↗
11. Chiche J. · J. Cell Mol. Med. · 2010 · 14 · 77110.1111/j.1582-4934.2009.00994.x ↗
12. López-Lázaro M. · Cancer Lett. · 2007 · 252 · 110.1016/j.canlet.2006.10.029 ↗
13. Hellman S. · 1997 · 307
14. Wu W. · Artif. Cells Blood Substit. Immobil. Biotechnol. · 2009 · 37 · 16310.1080/10731190903043218 ↗
15. Overgaard J. · Semin. Radiat. Oncol. · 1996 · 1010.1016/S1053-4296(96)80032-4 ↗
16. Gordijo C. R. · Adv. Func. Mater. · 2010 · 20 · 140410.1002/adfm.200901581 ↗
17. Luo X. L. · Biosens. Biolectron. · 2004 · 19 · 129510.1016/j.bios.2003.11.019 ↗
18. Yildirimer L. · Nano Today. · 2011 · 6 · 58510.1016/j.nantod.2011.10.001 ↗
19. Bai Y. · Electrochem. Commun. · 2007 · 9 · 261110.1016/j.elecom.2007.08.013 ↗
20. Liu X. · Analyst · 2012 · 137 · 455210.1039/c2an35700c ↗
21. Luo Y. · Mater. Lett. · 2007 · 61 · 189310.1016/j.matlet.2006.07.165 ↗
22. Kaibara K. · Biomacromolecules · 2000 · 1 · 10010.1021/bm990006k ↗
23. Alkilany A. M. · Small · 2009 · 5 · 70110.1002/smll.200801546 ↗
24. Halliwell B. · FEBS Lett. · 2000 · 486 · 1010.1016/S0014-5793(00)02197-9 ↗
25. Desai N. · Drug Delivery Rep. · 2007 · 37
26. Desai N. · Nanomed.: Nanotechnol., Biol. Med. · 2007 · 3 · 33910.1016/j.nano.2007.10.021 ↗
27. Desai N. · Transl. Oncol. · 2009 · 2 · 5910.1593/tlo.09109 ↗
28. Desai N. · Clin. Cancer Res. · 2006 · 12 · 131710.1158/1078-0432.CCR-05-1634 ↗
29. Zhang H. F. · Nat. Biotechnol. · 2006 · 34 · 84810.1038/nbt1220 ↗
30. Fukumura D. · Microcirculation · 2010 · 17 · 20610.1111/j.1549-8719.2010.00029.x ↗
31. Goldberg E. P. · J. Pharm. Pharmacol. · 2002 · 54 · 15910.1211/0022357021778268 ↗
32. Yang L. · Med. Hypotheses · 2009 · 73 · 33410.1016/j.mehy.2009.04.002 ↗
33. Hight M. R. · J. Biomed. Opt. · 2011 · 16 · 016007110.1117/1.3533264 ↗
34. Kalliomaki T. · Br. J. Cancer · 2004 · 90 · 184210.1038/sj.bjc.6601766 ↗
35. Gillies R. J. · IEEE Eng. Med. Biol. Mag. · 2004 · 23 · 5710.1109/MEMB.2004.1360409 ↗
36. Peyratout C. S. · Angew. Chem., Int. Ed. · 2004 · 43 · 376210.1002/anie.200300568 ↗
37. Rivera-Gill P. · ACS Nano · 2009 · 9 · 4398
38. Rademakers S. E. · BMC Cancer. · 2011 · 11 · 16710.1186/1471-2407-11-167 ↗
39. Wu H. · J. Cancer Mol. · 2008 · 4 · 37
40. Carmeliet P. · Nature · 2000 · 407 · 24910.1038/35025220 ↗
41. Moroz E. · PLoS ONE · 2009 · 4 · 1
42. Emil M. · Front. Oncol. · 2013 · 1
43. Maeda A. · PLoS ONE · 2012 · 7 · 1
44. Shalviri A. · Eur. J. Pharm. Biopharm. · 2012 · 82 · 58710.1016/j.ejpb.2012.09.001 ↗
45. Zhang F. · Chemphyschem. · 2010 · 11 · 73010.1002/cphc.200900849 ↗
46. del Mercato L. L. · Small · 2011 · 7 · 35110.1002/smll.201001144 ↗